About Rhythm Pharmaceuticals, Inc.
https://www.rhythmtx.comRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity.
CEO
David P. Meeker
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 152
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
Goldman Sachs
Buy
Canaccord Genuity
Buy
Needham
Buy
B of A Securities
Buy
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:419.1M
Value:$47.5B
BLACKROCK INC.
Shares:6.74M
Value:$764.13M
BLACKROCK, INC.
Shares:6.3M
Value:$714.29M
Summary
Showing Top 3 of 284
About Rhythm Pharmaceuticals, Inc.
https://www.rhythmtx.comRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $51.3M ▲ | $98.45M ▲ | $-52.9M ▼ | -103.13% ▼ | $-0.82 ▼ | $-47.75M ▼ |
| Q2-2025 | $48.5M ▲ | $88.25M ▲ | $-46.63M ▲ | -96.14% ▲ | $-0.75 ▲ | $-40.1M ▲ |
| Q1-2025 | $32.7M ▼ | $76.06M ▼ | $-49.5M ▼ | -151.35% ▼ | $-0.81 ▼ | $-43.63M ▼ |
| Q4-2024 | $41.83M ▲ | $79.3M ▲ | $-43.29M ▲ | -103.5% ▲ | $-0.72 ▼ | $-37.55M ▲ |
| Q3-2024 | $33.25M | $73.31M | $-43.64M | -131.25% | $-0.71 | $-38.36M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $416.05M ▲ | $506.87M ▲ | $358.06M ▼ | $148.82M ▲ |
| Q2-2025 | $291.03M ▼ | $372.73M ▼ | $384.64M ▲ | $-11.91M ▼ |
| Q1-2025 | $314.49M ▼ | $386.69M ▼ | $223.6M ▼ | $163.09M ▼ |
| Q4-2024 | $320.56M ▲ | $392.27M ▲ | $227.72M ▲ | $164.55M ▲ |
| Q3-2024 | $298.39M | $363.57M | $210.88M | $152.7M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-52.9M ▼ | $-26.62M ▼ | $-246.35M ▼ | $189.3M ▲ | $-83.36M ▼ | $-26.62M ▼ |
| Q2-2025 | $-46.63M ▲ | $-23.31M ▲ | $54.03M ▲ | $-889K ▼ | $29.55M ▲ | $-23.31M ▲ |
| Q1-2025 | $-49.5M ▼ | $-40.35M ▼ | $24.81M ▲ | $32.5M ▼ | $16.96M ▼ | $-40.35M ▼ |
| Q4-2024 | $-43.29M ▲ | $-18.84M ▲ | $21.16M ▲ | $38.33M ▲ | $41.62M ▲ | $-18.84M ▲ |
| Q3-2024 | $-43.64M | $-25.21M | $-90.82M | $2.49M | $-114.15M | $-25.21M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $-10.00M ▼ | $-10.00M ▲ | $-10.00M ▲ |
 Product | $100.00M ▲ | $50.00M ▼ | $40.00M ▼ | $50.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $10.00M ▲ | $20.00M ▲ | $10.00M ▼ |
 UNITED STATES | $70.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
David P. Meeker
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 152
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
Goldman Sachs
Buy
Canaccord Genuity
Buy
Needham
Buy
B of A Securities
Buy
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:419.1M
Value:$47.5B
BLACKROCK INC.
Shares:6.74M
Value:$764.13M
BLACKROCK, INC.
Shares:6.3M
Value:$714.29M
Summary
Showing Top 3 of 284